source
- Novartis expands molecular glue program as Medicare drug spending surges and biotech firms report new data and fundingNovartis announced it is deepening its investment in molecular glue technology, a platform that aims to target previously undruggable proteins. The move signals the company’s confidence in the appr…
- Enliven Therapeutics' early-stage study shows 48% major molecular response in CML patientsA targeted therapy from Enliven Therapeutics, ELVN-001, produced major molecular responses in 48% of participants with chronic myeloid leukemia (CML) in a 24‑week, early‑stage trial. The study eval…